Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C12N15/50

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.110951756表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN 03.04.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202010110070.8 Applicant 广州恩宝生物医药科技有限公司 Inventor 陈凌
本发明公开了表达SARS‑CoV‑2病毒抗原肽的核酸序列及其应用,核酸序列为SEQ ID NO.:1、SEQ ID NO.:2或其具有至少90%同源性的序列。本发明一些实例的核酸序列,可以在人体细胞中有效表达,产生相应的多肽,诱导产生相应的免疫保护反应,有望开发为SARS‑CoV‑2疫苗。
2.WO/2020/010474THE EBOLA VIRUS GLYCOPROTEIN AS A TOOL TO STIMULATE AN IMMUNE RESPONSE
WO 16.01.2020
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/CA2019/050975 Applicant UNIVERSITÉ LAVAL Inventor KOBINGER, Gary
Pseudotyped vesicular stomatitis viruses comprising the Ebola virus glycoprotein and antigens, as well as viral preparations and pharmaceutical composition for generating an immune response in a host or for vaccination are provided herewith. VSV-based vectors for preparing pseudotyped vesicular stomatitis viruses comprising the Ebola virus glycoprotein and antigens are also provided.
3.110616198New coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein
CN 27.12.2019
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No 201810628239.1 Applicant TSINGHUA UNIVERSITY Inventor ZHANG LINQI
The present invention discloses a new coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein. The recombinant adenovirus is obtained by transfecting an adenovirus packaging cell with a recombinant plasmid and then performing cell culture; the recombinant plasmid is obtained by inserting a specific DNA molecule into a delta-E1 region of a chimpanzee adenovirus vector AdC68; the specific DNA molecule has a full-length MERS-CoV Spike protein encoding gene; and the adenovirus packaging cell has an adenovirus E1 gene. The present invention also protectsthe recombinant adenovirus expressing the full-length MERS-CoV Spike protein; and a starting strain of the recombinant adenovirus is chimpanzee adenovirus type 68 or non-replicating chimpanzee adenovirus type 68. The developed vaccine against the new coronavirus MERS-CoV has important theoretical guidance value and broad application prospects, and provides a possibility for radical cure of MiddleEast respiratory syndrome.
4.2019535291プラス鎖RNAウイルスによって引き起こされる感染疾患に対するワクチン
JP 12.12.2019
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Appl.No 2019528043 Applicant メディジェン, インコーポレイテッド Inventor プシュコ, ピーター

(+)SS RNAウイルスによって生じる疾患から対象を防御するための組成物が、本明細書において記載されている。この組成物は、(i)真核生物RNAポリメラーゼプロモーターに作動可能に連結した感染性(+)SS RNAウイルスのRNA分子をコードするDNAを含有するベクターおよび担体を含むか、または(ii)(i)のベクターをトランスフェクトされた真核細胞から得られた(+)SS RNAウイルスおよび担体を含む。

5.2019176861VECTORS FOR TRANSFORMING MYCOPLASMA HYOPNEUMONIAE, TRANSFORMED MYCOPLASMA HYOPNEUMONIAE STRAINS AND THE USE THEREOF
JP 17.10.2019
Int.Class C12N 1/21
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
21modified by introduction of foreign genetic material
Appl.No 2019095908 Applicant HIPRA SCIENTIFIC SLU Inventor LUIS GONZALEZ GONZALEZ

PROBLEM TO BE SOLVED: To provide methods for engineering Mycoplasma hyopneumoniae in order to prepare transformed variant strains usable as vaccines against porcine diseases.

SOLUTION: Disclosed herein is a method for preparing a mutant strain of Mycoplasma hyopneumoniae (Mhyo), comprising a step of transforming a strain of M. hyopneumoniae using a carrier vector which comprises at least one heterogenous DNA sequence under the regulation of a DNA sequence in the promoter region of M. hyopneumoniae, where the carrier vector is selected from the group consisting of replication plasmid vectors and transposon vectors.

SELECTED DRAWING: None

COPYRIGHT: (C)2020,JPO&INPIT

6.110331171Method for efficiently and rapidly constructing porcine intestinal coronavirus recombinant virus
CN 15.10.2019
Int.Class C12N 15/90
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
90Stable introduction of foreign DNA into chromosome
Appl.No 201910626337.6 Applicant HUAZHONG AGRICULTURAL UNIVERSITY Inventor XIAO SHAOBO
The present invention belongs to the technical field of animal infectious disease prevention and control and specifically relates to a method for efficiently and rapidly constructing a porcine intestinal coronavirus recombinant virus. A BAC plasmid containing full-length cDNA of PEDV AJ1102 strain is cleaved by a CRISPR/Cas9 system, then a recombinant BAC plasmid of EGFP gene substituted with PEDVAJ1102 strain ORF3 gene is obtained by a homologous recombination method, and after transfecting cells, the recombinant virus rAJ1102-delta ORF3-EGFP is rescued. Since different porcine intestinal coronaviruses have similar genomic structure and replication strategies, the method is also suitable for construction of other porcine intestinal coronavirus recombinant viruses. Compared with traditional methods, the method has prominent advantages of wide target selection, high specificity, simple operation, high efficiency, short experimental period, etc., can obtain the recombinant virus withinone week, and is the method for efficiently and rapidly constructing the porcine intestinal coronavirus recombinant virus.
7.2019100990RECOMBINANT SHUTTLE PLASMID CONTAINING PORCINE EPIDEMIC DIARRHEA VIRUS S GENE, RECOMBINANT ADENOVIRUS, AND APPLICATION THEREOF
AU 19.09.2019
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 2019100990 Applicant Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences Inventor
The present invention provides a recombinant shuttle plasmid containing porcine epidemic diarrhea virus (PEDV) S gene, a recombinant adenovirus, and an application thereof, and relates to the technical field of genetic engineering vaccine. The recombinant adenovirus constructed by the present invention has a high titer, reaching up to 1x1011 PFU/mL, which can provide important support for clinically effective prevention and control of PEDV.
8.2019521987伝染性気管支炎ウイルスに対するワクチン
JP 08.08.2019
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 2018565802 Applicant ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Inventor ロッティエル ペトルス ヨゼーヒュス マリー

本発明は、一般に、IBV(伝染性気管支炎ウイルス)およびIBVを含む免疫原性組成物それぞれに関し、ORF3aおよび/またはORF3bおよび/またはORF5aおよび/またはORF5bが不活性化されている。さらに、本発明は、対象を免疫化する方法であって、そのような対象に本発明の免疫原性組成物を投与することを含む方法に関する。さらに、本発明は、必要性のある対象においてIBVによって引き起こされる臨床徴候を処置または予防する方法であって、前記対象に本発明による免疫原性組成物の治療有効量を投与することを含む方法に関する。

9.110093357Multi-epitope antigen of porcine epidemic diarrhea virus, and encoding gene, preparation method and application thereof
CN 06.08.2019
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 201910306949.7 Applicant ZHONGKAI UNIVERSITY OF AGRICULTURE AND ENGINEERING Inventor LIU WENJUN
The invention provides a gene encoding a multi-epitope antigen of porcine epidemic diarrhea virus, the multi-epitope antigen of the porcine epidemic diarrhea virus, and a preparation method of the multi-epitope antigen of the porcine epidemic diarrhea virus. The invention has the following advantages and beneficial effects: 1) the multi-epitope antigen of the porcine epidemic diarrhea virus is a multi-epitope antigen using norovirus P particles chimeric with the porcine epidemic diarrhea virus, natural structural proteins of pathogens are fully reduced, only main viral surface antigen proteinsare expressed, and nonspecific immunoreaction, strong virulence reversion and other problems induced by many irrelevant antigens are solved obviously; 2) the preparation method is low in preparationcost, short in time consuming and safety; and 3) the prepared multi-epitope antigen of the porcine epidemic diarrhea virus has good bioactivity and reactogenicity.
10.110041410New genetic engineering subunit vaccine for transmissible gastroenteritis virus of swine
CN 23.07.2019
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 201910304027.2 Applicant SUZHOU SHINUO BIO-TECH CO., LTD. Inventor CAO WENLONG
The present application provides an immunological composition and a subunit vaccine. The immunological composition comprises: a swine transmissible gastroenteritis virus S1 protein encoded by a nucleic acid molecule of SEQ ID NO:1 or a nucleic acid molecule of 95% or more identical to the nucleotide sequence of the SEQ ID NO:1. The vaccine uses an eukaryotic expression of CHO cells, is sufficientin protein glycosylation, good in antigen protein immunogenicity, and also very high in expression levels, and reaches 2-3 g/L. The recombinant cells can be subjected to suspension cultivation in a large scale, which greatly reduces complexity of vaccine preparation and saves production costs.